A Phase 3 trial of SB 9225 (inarigivir + tenofovir disoproxil fumarate)
Phase of Trial: Phase II/III
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Inarigivir-soproxil/tenofovir-disoproxil-fumarate (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 11 Mar 2019 According to a Spring Bank Pharmaceuticals media release, based on the results of the company's CATALYST Phase 2b inarigivir trials and the ongoing Gilead co-administration studies, the company could initiate this Phase 3 program for SB 9225 in 2020.
- 22 Mar 2018 New trial record
- 20 Mar 2018 According to a Spring Bank Pharmaceuticals media release, this trial is anticipated to initiate in 2019.